Pierre Fabre Pharmaceuticals Secures FDA Type A Meeting
SECAUCUS, N.J. — March 12, 2026 Pierre Fabre Pharmaceuticals announced that the U.S. Food and Drug Administration has agreed...
Biologics License Application
Advertisement
Gilead to Acquire Arcellx in $7.8B Cell Therapy Deal
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
FDA Priority Review Granted to Garetosmab for FOP
Rare Disease Biologic Advances Toward U.S. Approval – February 19, 2026 | Tarrytown, New York Regeneron Pharmaceuticals announced that...
Larimar’s Nomlabofusp Shows Long-Term Promise in Friedreich’s Ataxia
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
Nexiguran Ziclumeran Shows Durable Phase 1 Benefits in ATTR
CAMBRIDGE, Mass., Sept. 25, 2025 — Intellia Therapeutics announced positive longer-term Phase 1 data for its investigational CRISPR-based therapy...
Advertisement
